Abstract
Immunotherapy has brought about a radical change in the treatment landscape of cancer. However, only 20%–30% of patients with cancer show a durable clinical response to any of the available tumor immunotherapy approaches. Since tumor cells use a variety of pathways for their survival, resistance to immunotherapy in cancer is a multifactorial process. Interleukin-1 (IL-1) is one important cytokine that plays a crucial role in mediating resistance to immunotherapy. IL-1-mediated immunosuppression is characterized by multiple interlinked pathways including but not limited to metabolic rewiring and epigenetic modification of tumor cells, leading to acquired resistance to therapies. Therefore, novel combination therapies are essential to overcome drug resistance. This chapter details the role of IL-1 in cancer progression and how inhibiting IL-1 axes may help in maximizing the gains from cancer immunotherapy. Potential combination therapies that can be applied to overcome IL-1-mediated drug resistance are also discussed.
| Original language | English |
|---|---|
| Title of host publication | Multifaceted Role of IL-1 in Cancer and Inflammation |
| Publisher | Elsevier |
| Pages | 99-125 |
| Number of pages | 27 |
| ISBN (Electronic) | 9780128242735 |
| ISBN (Print) | 9780323859677 |
| DOIs | |
| State | Published - 1 Jan 2023 |
Bibliographical note
Publisher Copyright:© 2023 Elsevier Inc. All rights reserved.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- IL-1 inflammation and blockade therapy
- IL-1-mediated resistance
- Immunotherapy
- Strategies for therapeutic interventions
Fingerprint
Dive into the research topics of 'Strategies to overcome interleukin-1-mediated immune suppression and resistance to immunotherapy in cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver